MyFinsight
Home
Blog
About
Net (gain) income
attributable to common...
-$11,663K
Less allocation of
undistributed gain to...
-$3,665K
(-423.19%↓ Y/Y)
Net (gain) income
from consolidated...
-$14,270K
(-1005.46%↓ Y/Y)
Benefit (provision) for
income taxes
-$164K
Accretion of cullgen
redeemable convertible...
$1,058K
(gain) income before
income taxes
-$14,434K
Interest income
$740K
Change in fair value of
warrant liability
-$132K
Gyre
Pharmaceuticals
$29,097K
Gyre
$8K
(gain) income from
operations
-$14,363K
Other expense, net
-$943K
Revenues
$29,105K
(8.72%↑ Y/Y)
Total operating
expenses
$43,468K
Research and
development-Nonrelated Party
$14,300K
Selling and marketing
$13,754K
General and
administrative
$7,867K
Research and
development-Related Party
$4,836K
Cost of revenues
$2,209K
(91.92%↑ Y/Y)
Transaction costs
$502K
Back
Back
Income Statement
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)
source: myfinsight.com